Cargando…

Estimation of US patients with cancer who may respond to cytotoxic chemotherapy

AIMS, PATIENTS & METHODS: In this retrospective review, we sought to estimate the proportion of patients in the USA with advanced or metastatic cancer who are eligible for and may respond to recommended first-line cytotoxic chemotherapy based on National Comprehensive Cancer Network treatment gu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maldonado, Edward B, Parsons, Scott, Chen, Emerson Y, Haslam, Alyson, Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491026/ https://www.ncbi.nlm.nih.gov/pubmed/32983564 http://dx.doi.org/10.2144/fsoa-2020-0024

Ejemplares similares

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
por: Haslam, Alyson, et al.
Publicado: (2019)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
por: Haslam, Alyson, et al.
Publicado: (2020)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
por: Olivier, Timothée, et al.
Publicado: (2023)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Characteristics of Facebook’s third-party medical fact checkers
por: Haslam, Alyson, et al.
Publicado: (2022)

Comparability of Control and Comparison Groups in Studies Assessing Long COVID
por: Haslam, Alyson, et al.
Publicado: (2023)

Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non–Small Cell Lung Cancers
por: Parsons, Scott, et al.
Publicado: (2020)

Medical Reversals in Family Practice: A Review
por: Haslam, Alyson, et al.
Publicado: (2020)

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials
por: Olivier, Timothée, et al.
Publicado: (2022)

How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature
por: Haslam, Alyson, et al.
Publicado: (2022)

The frequency of assessment of progression in randomized oncology clinical trials
por: Haslam, Alyson, et al.
Publicado: (2021)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals
por: Haslam, Alyson, et al.
Publicado: (2023)

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
por: Olivier, Timothée, et al.
Publicado: (2023)

The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review
por: Bhatt, Anjali, et al.
Publicado: (2023)

Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use
por: Prasad, Vinay, et al.
Publicado: (2023)

The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009–2018
por: Haslam, Alyson, et al.
Publicado: (2021)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
por: de Almeida Carvalho, Lelia Maria, et al.
Publicado: (2019)

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials
por: Ahmed, Nibras, et al.
Publicado: (2022)

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers
por: Haslam, Alyson, et al.
Publicado: (2023)

Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals
por: Buck, Eva, et al.
Publicado: (2023)

Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity
por: Olivier, Timothée, et al.
Publicado: (2023)

Multiple myeloma: challenges with deciding the optimal sequencing strategy
por: Walia, Anushka, et al.
Publicado: (2023)

Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials
por: Haslam, Alyson, et al.
Publicado: (2020)

Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
por: Benjamin, David J., et al.
Publicado: (2022)

Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis
por: Banerjee, Titas, et al.
Publicado: (2023)

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)
por: Jenei, Kristina, et al.
Publicado: (2022)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

Perceptions of Hunting and Hunters by U.S. Respondents
por: Byrd, Elizabeth, et al.
Publicado: (2017)

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
por: Ngoi, N.Y.L., et al.
Publicado: (2018)

Response to ‘MacIntyre et al., 2020: A rapid systematic review of the efficacy of face masks and respirators against coronaviruses and other respiratory transmissible viruses for the community, healthcare workers and sick patient’
por: Haslam, Alyson
Publicado: (2020)

I Don’t Care Who You Are: Adult Respondent Selection Does Not Alter Child Deprivation Estimates
por: Lanau, Alba, et al.
Publicado: (2023)

Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis
por: Miao, Benjamin, et al.
Publicado: (2019)

Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy
por: Osuna-Gómez, Rubén, et al.
Publicado: (2021)

Cytotoxic T cells both produce and respond to interleukin 2
por: Andrus, L, et al.
Publicado: (1984)

Intensive Cytotoxic Chemotherapy
por: Bagshawe, K. D.
Publicado: (1971)

WHO working closely with countries responding to monkeypox
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8ppgan5vq8hvr6vjb1j176erkr